Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHEA: Izencitinib in Ulcerative Colitis
NCT03758443Phase 3Terminated
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of izencitinib in ulcerative colitis (UC) (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Change From Baseline in Total Mayo Score at Week 8 and Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Maintenance Week 44. Started Mar 2019; status: terminated.
02
Drugs
izencitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03758443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758443.